LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will participate in a virtual fireside chat at the 12th Annual Jefferies London Healthcare Conference from Nov. 16-19, 2021. The chat will be available from 3:00 a.m. ET on Nov. 18 until 12:00 p.m. ET on Nov. 19. LAVA's leadership will also engage in one-on-one investor meetings during the event. Attendees can register for the conference and access the recording of the chat on LAVA's investor relations website.
- None.
- None.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer at LAVA, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference taking place from Nov. 16-19, 2021. Members of the LAVA leadership team will also participate in virtual one-to-one investor meetings during the conference.
The fireside chat will be available to conference attendees starting at 3:00 a.m. ET (08:00 GMT) on Thurs., Nov. 18 through 12:00 p.m. ET (17:00 GMT) on Fri., Nov. 19. To register, please visit: Jefferies London Healthcare Conference.
Access to the recording will be available under the "Events" tab on the investor relations section of the Lava Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage biotechnology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the potential treatment of solid tumors and hematological malignancies. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells via the triggering of Vγ9Vδ2 T cell antitumor effector functions upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematological malignancies is currently enrolling (NCT04887259). The company currently anticipates data from the Phase 1 dose escalation phase of the study in the first half of 2022 with top line clinical data from the Phase 2a expansion cohorts expected in the second half of 2022. The company plans to initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer in the fourth quarter of 2021. For more information, please visit www.lavatherapeutics.com and follow us on LinkedIn and Twitter.
LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect of the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. In addition, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
CONTACTS
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com
Catherine Day
+1-917-763-2709
Catherine@newdaybioconsulting.com
FAQ
What is LAVA Therapeutics' participation in the Jefferies London Healthcare Conference?
When does the virtual fireside chat featuring Stephen Hurly take place?
How can I access the recording of the LAVA Therapeutics fireside chat?
What is LAVA Therapeutics' ticker symbol?
What type of therapies is LAVA Therapeutics focused on?
